Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference67 articles.
1. Src continues aging: current and future clinical directions;Kopetz;Clin Cancer Res,2007
2. N-(5-Chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor;Hennequin;J Med Chem,2006
3. Expression of Src and FAK in hepatocellular carcinoma and the effect of src inhibitors on hepatocellular carcinoma in vitro;Lau;Dig Dis Sci,2009
4. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumour activity in preclinical assays;Lombardo;J Med Chem,2004
5. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity;Boschelli;J Med Chem,2001
Cited by 61 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An insight into sustainable and green chemistry approaches for the synthesis of quinoline derivatives as anticancer agents;European Journal of Medicinal Chemistry;2024-09
2. Overcoming Secondary Mutations of Type II Kinase Inhibitors;Journal of Medicinal Chemistry;2024-06-05
3. Molybdenum-doped carbon nitride as an efficient heterogeneous catalyst for direct amination of nitroarenes with arylboronic acids;Chinese Chemical Letters;2024-05
4. Discovery of pyrimidine-5-carboxamide derivatives as novel salt-inducible kinases (SIKs) inhibitors for inflammatory bowel disease (IBD) treatment;European Journal of Medicinal Chemistry;2023-08
5. Can pharmacy students use Wikipedia as a learning resource? Critical assessment of articles on chemotherapeutic drugs;Advances in Physiology Education;2023-06-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3